Provided by Tiger Trade Technology Pte. Ltd.

Exagen

3.70
+0.29008.50%
Pre-market: 3.700.00000.00%04:43 EST
Volume:625.62K
Turnover:2.32M
Market Cap:83.85M
PE:-3.94
High:3.83
Open:3.42
Low:3.20
Close:3.41
52wk High:12.23
52wk Low:2.67
Shares:22.66M
Float Shares:14.35M
Volume Ratio:2.44
T/O Rate:4.36%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.9394
EPS(LYR):-0.8304
ROE:-122.81%
ROA:-14.66%
PB:4.62
PE(LYR):-4.46

Loading ...

BTIG Sticks to Their Buy Rating for Exagen (XGN)

TIPRANKS
·
Feb 17

Exagen Is Maintained at Buy by BTIG

Dow Jones
·
Feb 17

B. Riley Cuts Price Target on Exagen to $8 From $18, Keeps Buy Rating

MT Newswires Live
·
Jan 30

Exagen Price Target Cut to $8.00/Share From $18.00 by B. Riley Securities

Dow Jones
·
Jan 30

Exagen price target lowered to $8 from $18 at B. Riley

TIPRANKS
·
Jan 30

Exagen: Sustained Test Volume Growth and Solid Cash Runway Support Outperform Rating Despite Mixed Quarter

TIPRANKS
·
Jan 12

Exagen reports preliminary Q4 revenue $16M-$17M, consensus $17.19M

TIPRANKS
·
Jan 12

Exagen Inc. full year 2025 revenue rises to USD 66–67 million, up 19–20%

Reuters
·
Jan 12

Exagen Inc. Announces Select Preliminary 2025 Financial Results

GlobeNewswire
·
Jan 12

Exagen’s Strategic Growth and Innovation Drive Buy Rating Amid Market Expansion

TIPRANKS
·
Nov 18, 2025

Exagen Inc. to Participate in Craig-Hallum Alpha Select Conference

Reuters
·
Nov 11, 2025

Exagen Is Maintained at Buy by BTIG

Dow Jones
·
Nov 10, 2025

Exagen Inc : Btig Raises Target Price to $15 From $13

THOMSON REUTERS
·
Nov 10, 2025

Earnings Update: Here's Why Analysts Just Lifted Their Exagen Inc. (NASDAQ:XGN) Price Target To US$14.43

Simply Wall St.
·
Nov 07, 2025

Exagen’s Earnings Call: Growth Amid Financial Hurdles

TIPRANKS
·
Nov 05, 2025

Exagen’s Growth Potential Amid ASP Challenges: A Positive Long-Term Investment Outlook

TIPRANKS
·
Nov 05, 2025

Exagen’s Strong Volume Growth and Market Penetration Support Buy Rating Despite Temporary ASP Setbacks

TIPRANKS
·
Nov 05, 2025

Exagen Q3 revenue beats analyst expectations

Reuters
·
Nov 04, 2025

BRIEF-Exagen Inc. Q3 Revenue USD 17.244 Million Vs. IBES Estimate USD 16.9 Million

Reuters
·
Nov 04, 2025

Exagen Inc. Q3 Operating Expenses USD 13.175 Million

THOMSON REUTERS
·
Nov 04, 2025